Two phase III clinical trials (ORIENT-32 and IMbrave150) revealed a survival advantage of ICIs plus anti-VEGF drugs compared with the standard treatment (sorafenib) for unresectable HCC (Finn et al., 2020a; Ren et al., 2021). This evidence concerns the gene VEGFA and hepatocellular carcinoma.